Ishita Drugs & Industries Ltd has notified BSE Limited that SEBI Regulation 32(1) regarding statement of deviation from proceeds is not applicable to the company for the financial year ended 31st March, 2026. The pharmaceutical company confirmed it did not undertake any fund raising activities during this period.

Regulatory Compliance Communication

In a formal communication dated 13th April, 2026, Ishita Drugs & Industries Ltd addressed the Department of Corporate Services at BSE Limited regarding the non-applicability of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company specifically referenced Regulation 32(1), which mandates submission of statements regarding deviation or variation from proceeds of various fund raising mechanisms.

Fund Raising Activities Status

The company explicitly stated that it has not raised any funds through the following mechanisms during FY26:

• Public issue
• Rights issue
• Preferential issue
• Qualified Institutional Placement (QIP)

Due to the absence of any such fund raising activities, the company confirmed that the statement of deviation or variation is not being provided as the regulation is not applicable.

Corporate Authorization

The communication was digitally signed and authorized by Jagdish Agrawal, Managing Director of Ishita Drugs & Industries Ltd, bearing DIN 01031687. The document was submitted to BSE Limited for their records and acknowledgment.

This regulatory filing demonstrates the company's commitment to maintaining transparency and compliance with SEBI listing obligations, even when specific regulations are not applicable to their operations during the reporting period.

Ishita Drugs and Industries Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The certificate pertains to the quarter ended March 31, 2026, and was submitted on April 10, 2026.

Regulatory Compliance Details

The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting on dematerialization activities. The document was prepared by Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent (RTA).

Certificate Confirmation

Bigshare Services Private Limited confirmed in their certificate dated March 31, 2026, that no securities were received from depository participants for dematerialization during the quarter from December 31, 2025 to March 31, 2026. Consequently, no certificates were mutilated and cancelled, and no substitution of depositories' names occurred in the register of members.

The RTA's confirmation specifically states that since there were no securities for dematerialization, there was no requirement for certificate substitution within the mandated 15-day period as per regulatory guidelines.

Corporate Information

The submission was signed by Jagdish Agrawal, Managing Director (DIN: 01031687), on behalf of Ishita Drugs and Industries Limited. The company operates with its corporate office located at 401, 3rd Eye II, Opposite Parimal Garden, C.G. Road, Ahmedabad-380006, and its registered office and factory at 179/1, Vasna-Iyava, Tal. Sanand, District Ahmedabad.

Regulatory Framework

This certificate submission aligns with SEBI circulars NSDL/CIR/II/5/2019 and CDSL/OPS/RTA/POLICY/2019/14, both dated January 25, 2019, along with SEBI letter reference MRD/DOP2/DSA2/OW/2019/2498/1 dated January 24, 2019. These regulations ensure transparency in dematerialization processes and maintain accurate records of securities transactions.